Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20828259 | 0.85 | POLB (0.64) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL20828257 | 0.80 | ALDH1A1 (0.53) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL7090889 | 0.79 | HSD17B10 (0.66) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL7091477 | 0.78 | POLB (0.56) | HSD17B10ALDH1A1HPGDPOLBXDH | |
| SCHEMBL11740275 | 0.78 | ALDH1A1 (0.59) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL6300081 | 0.77 | SIRT1 (0.54) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL11736095 | 0.77 | ALDH1A1 (0.46) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL7038229 | 0.77 | ALDH1A1 (0.56) | HSD17B10ALDH1A1HPGDKDM4EPLA2G10 | |
| SCHEMBL7545210 | 0.76 | HSD17B10 (0.49) | HSD17B10ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL10853903 | 0.74 | ALDH1A1 (0.64) | HSD17B10ALDH1A1HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | claimed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | claimed |
| US-20200270216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING N-SMASE2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-27 | — | — | US | disclosed |
| US-10441588-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-10-15 | — | — | US | disclosed |
| US-10441588-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2844258-B1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | UNIV MICHIGAN REGENTS (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2844258-B1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | UNIV MICHIGAN REGENTS (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2019055832-A1 | COMPOSITIONS AND METHODS FOR INHIBITING N-SMASE2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180042928-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | Nanova, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-20180042928-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | Nanova, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9814719-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2844258-A2 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | The Regents Of The University Of Michigan (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013166282-A2 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-11-07 | — | — | WO | disclosed |
| US-RE37979-E1 | Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof | MITSUBISHI CHEMICAL CORPORATION | 2003-02-04 | — | — | US | disclosed |
| EP-0829476-B1 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | MITSUBISHI CHEM CORP (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0829476-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5461060-A | Antiretroviral activity | MITSUBISHI KASEI CORPORATION (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0420763-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441588-B2 | Methods and compositions for treating bacterial infection | MMP8, CUTA, ELANE | HSD17B10 1891/4885ALDH1A1 2604/4885HPGD 843/4885 |
| US-20180042928-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | MMP8, CUTA, ELANE | HSD17B10 1891/4885ALDH1A1 2604/4885HPGD 843/4885 |
| US-20200270216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING N-SMASE2 | SMN1; SMN2, PSEN2, SMPD2 | HSD17B10 1232/4885ALDH1A1 3977/4885HPGD 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.